The safety use in pregnant women and nursing mothers has not been established, however, studies in several animals have not revealed any teratogenicity or fetotoxicity.
It is not recommended to be given to those with hepatobiliary disorders, since determination of dosage in those patients is on study.
It should be used with caution in patients with hepatic function impairment.
Inappropriate usage may raise resistant strains.
Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been seen in treatment with macrolides, therefore caution is required when treating: Patients with congenital or documented QT prolongation.
Patients currently receiving treatment with other active substances known to prolong QT interval such as antiarrhythmics of classes IA and III; antipsychotic agents; antidepressants; and fluoroquinolones.
Patients with electrolyte disturbance, particularly in cases of hypokalemia and hypomagnesemia.
Patients with clinically relevant bradycardia, cardiac arrhythmia or cardiac insufficiency.
Elderly patients: Elderly patients may be more susceptible to drug-associated effects on the QT interval.